CASIF · CASI Pharmaceuticals, Inc.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CASIF
this stock
CASI Pharmaceuticals, Inc.
|
$2.65M | -84.7% | -27.4% | — | 0.7% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +5.7% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -13.5% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$55.61B | +5.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Reported
- 1 of 1
- Top holder
- SIMPLEX TRADING, LLC
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CASIF | -7.1% | +0.0% | -86.9% | -23.5% | -84.7% |
| SPY | -0.6% | +0.7% | +6.8% | -1.0% | +8.4% |
| vs SPY | -6.6% | -0.7% | -93.7% | -22.5% | -93.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.